Citations

Mayo Clinic

Showing 10 of 108599 citations.

Bostwick, David G., Lieber, Michael M., Jenkins, Robert B. , Qian, J.

The Japanese Journal of Urology | April 6, 2017 | Volume: 89 | Issue: 2 | Pages: 267

10.5980/jpnjurol.89.267_2 Get It

HA, Guess, CJ, Girman, SJ, Jacobsen, MM, Lieber, Ha, Guess, Girman, Cynthia J. , Jacobsen, S. J.

The Japanese Journal of Urology | April 6, 2017 | Volume: 88 | Issue: 2 | Pages: 316

10.5980/jpnjurol.88.316_4 Get It

CJ, Girman, HA, Guess, MM, Lieber, Girman, Cynthia J. , Ha, Guess

The Japanese Journal of Urology | April 6, 2017 | Volume: 87 | Issue: 2 | Pages: 468

10.5980/jpnjurol.87.468_1 Get It

Lieber, Michael M., Jenkins, Robert B.

The Japanese Journal of Urology | April 6, 2017 | Volume: 87 | Issue: 2 | Pages: 283

10.5980/jpnjurol.87.283_1 Get It

Hogen, Kristine L., Tindall, D. J., Young, Charles Y.F.

The Japanese Journal of Urology | April 6, 2017 | Volume: 86 | Issue: 3 | Pages: 427

10.5980/jpnjurol.86.427_2 Get It

Screening for Endocrine Hypertension: An Endocrine Society Scientific Statement
Calhoun, David A. , Lenders, Jacques W.M. , Textor, Stephen C., Young, William F. , Stowasser, Michael

Endocrine Reviews | April 6, 2017 | Volume: 38 | Issue: 2 | Pages: 103-122

10.1210/er.2017-00054 Get It

Rotavirus Vaccine Schedules and Vaccine Response Among Infants in Low- and Middle-Income Countries: A Systematic Review
Gruber, Joann F. , Gruber, Lucinda , Weber, Rachel Palmieri , Becker‐Dreps, Sylvia , Funk, Michele Jönsson , Gruber, Lucinda M

Open Forum Infectious Diseases | April 6, 2017 | Volume: 4 | Issue: 2 | Pages: No page available

10.1093/ofid/ofx066 | PMID 28567431 Get It

Abstract Background Rotavirus vaccine schedules may impact vaccine response among children in low- and middle-income countries (LMICs). Our objective was to review the literature evaluating the effects of monovalent (RV1) or pentavalent rotavirus vaccines schedules on vaccine response. Methods We searched PubMed, Web of Science, Embase, and ClinicalTrials.gov for eligible trials conducted in LMICs comparing ≥2 vaccine schedules and reporting immunologic response or efficacy. We calculated seroconversion proportion differences and geometric mean concentration (GMC) ratios with 95% confidence intervals. Results We abstracted data from 8 eligible trials of RV1. The point estimates for seroconversion proportions difference ranged from −0.25 to −0.09 for the 6/10-week schedule compared with 10/14. The range for the 6/10/14- compared with 10/14-week schedule was −0.02 to 0.10. Patterns were similar for GMC ratios and efficacy estimates. Conclusions The commonly used 6/10-week RV1 schedule in LMICs may not be optimal. Further research on the effect of rotavirus schedules using clinical endpoints is essential.
Randomized controlled trials in mild cognitive impairment
Petersen, Ronald C. , Thomas, Ronald G. , Aisen, Paul, Mohs, Richard C. , Carrillo, María C. , Albert, Marilyn S.

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1751-1758

10.1212/wnl.0000000000003907 | PMID 28381516 Get It

A phase 3 trial of IV immunoglobulin for Alzheimer disease
Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Jack, Clifford R., Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Sadowski, Martin, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Hsiung, Robin, Schultz, Susan, Burns, Jeffrey, Jicha, Gregory, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R. , Hsiung, Ging‐Yuek Robin , Jicha, Gregory A. , Sadowski, Martin , van Dyck, Christopher H, Relkin, Norman R., Thomas, Ronald G., Rissman, Robert A., Brewer, James B., Rafii, Michael S., Dyck, Christopher H. van, Sano, Mary, Knopman, David S., Raman, Rema, Szabo, Paul, Gelmont, David M., Fritsch, Sandor, Aisen, Paul S., Study, For the Alzheimer's Disease Cooperative, Study, Alzheimer's Disease Cooperative, Ahern, Geoffrey, Yaari, Roy, Sabbagh, Marwan, Mirza, Nadeem, Bernick, Charles, Bell, Karen, Turner, R. Scott, Obisesan, Thomas, Chertkow, Howard, Zabar, Yuval, Knopman, David, Mintzer, Jacobo, Grossman, Hillel, Wu, Chuang-Kuo, Quinn, Joseph, Borrie, Michael, Petrie, William, Ott, Brian, Keegan, Andrew, Grossberg, George, Sabbagh, Marwan, Bari, Moammed, Cohen, Sharon, Richter, Ralph, Lerner, Alan, Mulnard, Ruth, Potkin, Steven, Rafii, Michael, Brockington, John, Schultz, Susan, Burns, Jeffrey, Burke, William, Arnold, Steven, Porsteinsson, Anton, Smith, Amanda, Schneider, Lon, Quiceno, Mary, Zamrini, Edward, Asthana, Sanjay, Burgat, FT, Duara, Ranjan, Dyck, Christopher van, Jack, Clifford R , Hsiung, Gink-Yuek , Jicha, Gregory A

Neurology | April 6, 2017 | Volume: 88 | Issue: 18 | Pages: 1768-1775

10.1212/wnl.0000000000003904 | PMID 28381506 Get It

2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheum
Rider, Lisa G. , Ruperto, Nicolino , Bayat, Nastaran, Amato, Anthony A. , Dastmalchi, Maryam, Katz, James D. , Mammen, Andrew L. , Visser, Marianne de, Ytterberg, Steven R. , Lundberg, Ingrid E. , Chung, Lorinda, Dankó, Katalin , Torre, Ignacio García‐De La , Villa, Luca, Rinaldi, Mariangela, Rockette, Howard E., Lachenbruch, Peter A., Miller, Frederick W. , Vencovský, Jiří , Rouster‐Stevens, Kelly , Huber, Adam M. , Selva-O’Callaghan, Albert , Rutkove, Seward B. , Dimachkie, Mazen M. , Olesińska, Marzena , Chung, Leland W.K. , Shinjo, Samuel Katsuyuki , Ramchandren, Sindhu , Saketkoo, Lesley Ann , Mann, H. , Aggarwal, Rohit , Erman, Brian , Feldman, Brian Michael , Oddis, Chester V. , Chinoy, Hector , Cooper, Robert G. , Fiorentino, David Franklin , Isenberg, David , Visser, Marianne de, Chung, Lorinda, Song, Yeong Wook , Mann, Heřman , Vencovsky, Jiri , Shinjo, Samuel Katsuyuki , Selva O'Callaghan, Albert , Chung, Lorinda , García-De La Torre, Ignacio , Dimachkie, Mazen M , Lundberg, Ingrid E , Pistorio, Angela

Arthritis & Rheumatology | April 6, 2017 | Volume: 69 | Issue: 5 | Pages: 898-910

10.1002/art.40064 | PMID 28382787 Get It

ObjectiveTo develop response criteria for adult dermatomyositis (DM) and polymyositis (PM).MethodsExpert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus.ResultsConsensus was reached for a conjoint analysis–based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0–100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P < 0.001).ConclusionThe response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.